Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer: A Phase II Southwest Oncology Group Study (S0339)  by Davies, Angela M. et al.
ORIGINAL ARTICLE
Bortezomib Plus Gemcitabine/Carboplatin as First-Line
Treatment of Advanced Non-small Cell Lung Cancer
A Phase II Southwest Oncology Group Study (S0339)
Angela M. Davies, MD, FRCPC,* Kari Chansky, MS,† Primo N. Lara, Jr, MD,*
Paul H. Gumerlock, PhD,* John Crowley, PhD,† Kathy S. Albain, MD,‡ Stanley J. Vogel, MD,§
and David R. Gandara, MD*
Introduction: Bortezomib is a small-molecule proteasome inhibitor
with single-agent activity in patients with non-small cell lung
carcinoma (NSCLC) and synergy with gemcitabine in preclinical
studies. This phase II study of bortezomib in combination with
gemcitabine/carboplatin was conducted in chemotherapy-naive ad-
vanced NSCLC patients to assess efficacy and safety.
Methods: Patients with selected stage IIIB/IV NSCLC, performance
status 0–1, and no history of brain metastasis received up to six
21-day cycles of gemcitabine 1000 mg/m2, days 1 and 8, carboplatin
area under curve 5.0, day 1, and bortezomib 1.0 mg/m2, days 1, 4,
8, and 11.
Results: One-hundred-fourteen patients (52% adenocarcinoma,
85% stage IV) received a median of 3.6 treatment cycles. Median
follow-up was 3 years. Median overall survival was 11 months;
1-year and 2-year survival rates were 47% and 19%, respectively.
Median progression-free survival was 5 months; 1-year progression-
free survival rate was 7%. Response rate was 23%, and disease
control rate (responses  stable disease) was 68%. The most
common grade 3/4 toxicities were thrombocytopenia (63%) and
neutropenia (52%). One patient experienced febrile neutropenia.
Grade 3/4 neuropathy occurred in 4%, and a further 6% experienced
grade 2 sensory neuropathy.
Conclusions: Bortezomib plus gemcitabine/carboplatin resulted in a
notable survival benefit in patients with advanced NSCLC, with the
anticipated primary toxicity of myelosuppression. Further studies
designed to investigate the role of bortezomib in advanced NSCLC
are warranted.
Key Words: Advanced NSCLC, Bortezomib, Carboplatin, Gemcit-
abine, Proteasome, Stage IV.
(J Thorac Oncol. 2009;4: 87–92)
For the past decade, doublet chemotherapy with cisplatin orcarboplatin plus a third-generation drug (paclitaxel, do-
cetaxel, vinorelbine or gemcitabine) has been considered the
standard of care for first-line treatment of advanced non-small
cell lung carcinoma (NSCLC).1–8 Gemcitabine/carboplatin is
a commonly used regimen due to its favorable toxicity
profile.4,5,7,9–12 Despite the benefits of chemotherapy, prog-
nosis for these patients remains poor,1,8,13 with median over-
all survival (OS) of typically 8 to 10 months and 1-year
survival rates of 35 to 40%.1,8 Thus, integrating novel agents
into front-line therapy is of tremendous interest and impor-
tance in advancing the field of lung cancer and patient
outcomes.
Bortezomib (VELCADE®, Millennium: The Takeda
Oncology Company, and Johnson & Johnson Pharmaceutical
Research & Development, LLC) inhibits the 26S proteasome,
thereby affecting the levels of numerous proteins involved in
processes such as cell-cycle control, apoptosis, cell adhesion,
angiogenesis, and chemoresistance.14,15 Bortezomib disrupts
multiple cellular pathways shown to be important in
NSCLC.14–16 In particular, most NSCLC cells have a dys-
regulated apoptotic pathway involving activated nuclear fac-
tor-B (NF-B).17 NF-B activates the transcription of anti-
apoptotic and proliferation genes, mediating tumor cell
survival in response to cytotoxic stress and resulting in
chemoresistance. Bortezomib attenuates this pathway by pre-
venting proteasomal degradation of IB, the inhibitor of
NF-B.14,15 Bortezomib also modulates levels of the anti-
apoptotic gene Bcl-2 and the tumor suppressor p53.14–16
Overexpression of Bcl-2, a key mediator of resistance to
apoptosis following chemotherapy, is evident in 70 to 80% of
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NSCLC cases, while mutations leading to functional loss or
decreased expression of p53 are present in up to 50% of
cases.14–16
Bortezomib has demonstrated single-agent antitumor
activity in NSCLC, both in preclinical18–20 and in early-phase
clinical studies.21–23 In preclinical studies, bortezomib sensi-
tized NSCLC and pancreatic cancer cells to gemcitabine-
induced apoptosis in vitro and in vivo,24,25 and sequence-
dependent enhanced activity was observed with bortezomib
plus gemcitabine/carboplatin in NSCLC cells.26 A phase I
California Cancer Consortium study demonstrated bort-
ezomib plus gemcitabine/carboplatin to be well tolerated
in patients with advanced NSCLC, with the primary tox-
icity being myelosuppression. The maximum tolerated
dose was determined to be bortezomib 1.0 mg/m2 on days
1, 4, 8, and 11, gemcitabine 1000 mg/m2 on days 1 and 8,
and carboplatin area under curve (AUC) 5.0 on day 1, in
21-day treatment cycles.27 The combination showed en-
couraging activity. Here, we report the subsequent South-
west Oncology Group (SWOG) phase II study to evaluate
the efficacy and toxicity of this regimen as first-line
treatment in patients with advanced NSCLC.
METHODS
Patients
Chemotherapy-naive patients with histologically or cy-
tologically proven selected stage IIIB (T4 lesion due to
malignant pleural effusion) or stage IV NSCLC were eligible.
Patients were required to have measurable or assessable
disease, and to have a SWOG performance status of 0–1.
Patients with recurrent disease following previous surgery
and/or radiation were also eligible. Recurrent disease had to
be outside previous radiation fields or have a new lesion
inside the field. Patients with brain metastases were not
eligible. Adequate organ function was required: serum creat-
inine less than or equal to the institutional limit of normal, or
calculated creatinine clearance of 60 ml/min (Cockcroft-
Gault formula28); absolute neutrophil count 1500 cells/l;
platelets 100,000 cells/l; and adequate hepatic function.
Patients with grade 2 peripheral neuropathy (based on
National Cancer Institute Common Terminology Criteria for
Adverse Events version 3.0) were excluded. No other prior
malignancies were allowed except adequately treated basal
cell or squamous cell skin cancer, in situ cervical cancer, or
other cancers from which the patient had been disease-free
for 5 years. Eligibility criteria were consistent with previous
SWOG trials in advanced NSCLC.12,29–31 The Institutional
Review Board at each participating institution approved the
study; all patients gave written informed consent in accor-
dance with institutional and federal guidelines before under-
going any study-related procedures.
Study Design
Patients were accrued at 33 SWOG institutions between
February and September 2004. Data cutoff for this report was
October 11, 2007. Dosing was based on the maximum toler-
ated dose in the California Cancer Consortium phase I study
of this combination.27 Patients received gemcitabine 1000
mg/m2 on days 1 and 8, carboplatin AUC 5.0 on day 1, and
bortezomib 1.0 mg/m2 on days 1, 4, 8, and 11, in 21-day
treatment cycles. Bortezomib was administered 60 minutes
after gemcitabine/carboplatin on days 1 and 8, based on
preclinical data demonstrating sequence specificity.26 Patients
without progression could receive up to six treatment cycles
of the triplet regimen; those tolerating treatment and without
disease progression could continue receiving bortezomib
alone for up to 1 year.
Gemcitabine/carboplatin dose reductions were required
for treatment delays of 7 days due to neutropenia and/or
thrombocytopenia, or significant hematologic or nonhemato-
logic toxicities in the preceding cycle. Bortezomib dose
reductions (to 0.8 mg/m2, then 0.6 mg/m2) were required for
unacceptable hematologic toxicities that persisted following
gemcitabine/carboplatin dose reduction, and for any grade
2 neurologic toxicities.
Supportive care, including use of antiemetics, was at
the discretion of the treating physician. Routine use of gran-
ulocyte colony-stimulating factors was not permitted; admin-
istration had to follow American Society of Clinical Oncol-
ogy guidelines and be discontinued 48 hours before the start
of the next cycle.
Evaluations
The primary objective of this phase II study was to
assess OS. Progression-free survival (PFS), response rate,
and safety were secondary objectives. Patient archival spec-
imens and blood samples were submitted for exploratory
molecular analyses. Radiologic investigations occurred at
baseline and every 6 weeks during treatment, and re-
sponses were evaluated according to Response Evaluation
Criteria in Solid Tumors.32 Safety was assessed throughout
the study; toxicities were graded according to National
Cancer Institute Common Terminology Criteria for Ad-
verse Events version 3.0.
Statistical Analyses
Target accrual was 99 patients, to provide 85% power
to exclude the null hypothesis of an 8-month median OS at
the 0.05 alpha level versus an alternative of a 12-month
median OS. Median OS of 10 months was considered as
warranting phase III testing of gemcitabine/carboplatin 
bortezomib. The target accrual allowed for estimation of
response and toxicity rates to within 10% (95% confidence
interval [CI]). OS and PFS were evaluated by Kaplan–Meier
methods.
RESULTS
Of 121 patients accrued, 6 were ineligible due to the
following: timing of registration following surgery, elevated
SGOT and bilirubin levels, low creatinine clearance, lack of
stage information, and timing of disease assessment (n  2).
One additional patient did not receive treatment. Of the 114
patients that were treated, 2 patients completed planned
treatment with 6 cycles of gemcitabine/carboplatin/bort-
ezomib and single-agent bortezomib for a total of 1 year; 112
patients discontinued treatment due to progression/relapse
(n  55), adverse events (AEs, n  44), refusal unrelated to
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AEs (n  6), death (n  3; all unrelated to treatment), and
other nonspecified reasons (n  4). Baseline patient charac-
teristics are shown in Table 1. Slightly more than half of
patients had adenocarcinoma, and 85% had stage IV NSCLC.
Patients received a median of 4 treatment cycles. Median
follow-up was 3 years.
Efficacy
Median OS was 11 months (95% CI: 8.2–13.4 months)
(Figure 1). Survival rates at 1 and 2 years were 47% and 19%,
respectively. Median PFS was 5 months (95% CI: 3.5–5.3
months) (Figure 2). The 1-year PFS rate was 7%. Best
response to therapy is shown in Table 2. The overall response
rate (ORR) for all 114 registered patients was 23%, with a
disease control rate (ORR  stable disease) of 68%. Subse-
quent therapies received following termination from study
protocol are shown in Table 3.
Safety
A total of 113 patients were evaluable for safety;
AEs were not reported for one patient. The most common
grade 3 and 4 AEs are shown in Table 4. While the
incidences of grade 3/4 thrombocytopenia and neutropenia
were 63% and 52%, respectively, only 3 patients (3%) had
grade 3 hemorrhage (associated with grade 4 thrombocy-
topenia, grade 3 thrombocytopenia, and no thrombocyto-
penia, respectively) and 1 patient (1%) had febrile neutro-
penia. Sensory neuropathy was seen in 26 patients (23%),
including 16 (14%) with grade 1, 7 (6%) with grade 2, and
3 (3%) with grade 3/4 toxicity. In total, 99 (87%) patients
were reported as requiring dose reductions during the first
6 cycles of treatment. The most common AEs resulting in
dose reduction were neutropenia and thrombocytopenia.
There were four deaths possibly related to treatment, one
due to multiorgan failure, one due to pneumonitis, one due
to diarrhea and dehydration, and one sudden death in a
patient with grade 4 thrombosis/embolism and grade 4
thrombocytopenia.
DISCUSSION
Modern platinum-based chemotherapy is associated
with benefits in survival, symptom palliation and quality of
life in patients with advanced NSCLC. Nevertheless, the
overall impact is modest at best, and novel approaches are
needed. Bortezomib both potentiates chemotherapy in
NSCLC cell lines and has demonstrated single-agent ac-
tivity in clinical trials. Gemcitabine/carboplatin was se-
lected as the chemotherapeutic backbone for S0339 be-
cause it is largely devoid of neuropathy, a potential
FIGURE 1. Kaplan–Meier curve for overall survival (n  114).
FIGURE 2. Kaplan–Meier curve for progression-free survival
(n  114).
TABLE 1. Baseline Patient Characteristics (n  114)
Parameter n %
Median age, years (range) 64 (28–79)
Male 69 61
Race
White 103 90
Black 4 4
Asian 3 3
Native American 1 1
Multi-racial 1 1
Unknown 2 2
Histology
Adenocarcinoma 59 52
Squamous cell 23 20
Large cell 7 6
Bronchioloalveolar 4 4
NSCLC, NOS 1 1
Other 20 18
Performance status
0 50 44
1 64 56
Disease stage
IIIB 14 12
IV 97 85
Recurrent 3 3
Prior surgery 16 14
Prior radiotherapy 20 18
Weight loss during past 6
mo
5% 79 69
5% 32 28
Missing 3 3
Smoking history was not collected at the time this study was conducted.
Percentages in categories do not necessarily total 100% due to rounding.
NOS, not otherwise specified; NSCLC, non-small cell lung cancer.
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overlapping toxicity with other agents commonly used in
NSCLC, and because of encouraging data in in vitro and in
vivo models with this three-drug regimen. Indeed, the
median OS of 11 months and 1-year survival of 47%
achieved in this phase II study surpass results of prior
SWOG trials (S9509, S9806, S0003) in advanced
NSCLC.12,29,31 Historically, recent SWOG studies in ad-
vanced NSCLC have maintained consistent eligibility cri-
teria and therefore patient populations have been relatively
comparable from study to study.12,29–31 In addition, all
studies were conducted in the era of positron emission
tomography scanning for disease staging, minimizing the
possibility that the prolonged survival seen in this study
compared with historical data may be related to stage-
migration effects. The survival data reported here are
further validated by the multi-institutional, cooperative-
group nature of our study, and by the large number of
patients enrolled.
While our survival results exceeded the predefined
statistical end point for proceeding with phase III investiga-
tion of gemcitabine/carboplatin plus bortezomib compared
with gemcitabine/carboplatin alone, it is important to note
that changes in the therapeutic landscape for advanced
NSCLC have occurred since our study was initiated. Most
notably, the Eastern Cooperative Oncology Group (ECOG)
4599 study of paclitaxel/carboplatin alone or in combina-
tion with bevacizumab, which demonstrated a significant
TABLE 2. Response to Therapy by RECIST
Response
Measurable
disease
(n  108)
Nonmeasurable
disease
(n  6)
All patients
(n  114)
n % n % n %
CR/CRu 0/2 0/2 0 0 0/2 0/2
PR/PRu 12/12 11/11 0 0 12/12 11/11
ORR (CR  PR) 26 24 0 0 26 23
SD 49 45 3 50 52 46
Disease control rate (ORR  SD) 75 69 3 50 78 68
PD 19 18 2 33 21 18
Assessment inadequate 14 13 1 17 15 13
CR, complete response; CRu, unconfirmed CR; ORR, overall response rate; PD, progressive disease (includes assessments of
increasing disease and symptomatic deterioration); PR, partial response; PRu, unconfirmed PR; SD, stable disease.
TABLE 3. Subsequent Regimens Received as Second-Line
Therapy after Bortezomib Plus Gemcitabine/Carboplatin on
Study Protocol (n  114)
Subsequent therapy n %
Any second-line therapy 82 72
No second-line therapy 29 25
Second-line therapy unknown 3 3
Third-line therapy and beyond 8 7
Second-line regimens
Pemetrexed 12 11
Docetaxel 11 10
EGFR-TKIsa 14 12
Platinum doubletb 30 26
Nonplatinum doublet (erlotinib/docetaxel) 1 1
Others 9 8
Radiotherapy 7 6
Cisplatin 1 1
Vinorelbine 1 1
Not specified 5 4
a Epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib.
b Includes 23 (20%) patients who received gemcitabine/carboplatin, of whom three
also continued with bortezomib, i.e., received the triplet regimen investigated in this
study, after officially terminating on-study treatment due to requiring more than two
dose reductions.
EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitors.
TABLE 4. Most Common Grade 3 Hematologic and
Nonhematologic Toxicities (n  113)
Adverse event
Total
grade >3 Grade 3 Grade 4
n % n % n %
Hematologic toxicities
Thrombocytopenia 71 63 30 27 41 36
Neutropenia 59 52 37 33 22 19
Anemia 15 13 13 12 2 2
Nonhematologic
toxicities
Fatigue 15 13 12 11 3 3
ALT/AST 14 12 13 12 1 1
Neuropathy 5 4 3 3 2 2
Dehydration 5 4 5 4 – –
Hypokalemia 4 4 3 3 1 1
Pneumonitis 4a 4 3 3 – –
Anorexia 3 3 3 3 – –
Diarrhea 3 3 3 3 – –
Dyspnea 3 3 3 3 – –
Hyponatremia 3 3 3 3 – –
Hypotension 3 3 2 2 1 1
Lung infection 3 3 3 3 – –
Nausea 3 3 3 3 – –
Thrombosis/embolism 3 3 2 2 1 1
a Includes one grade 5 event.
ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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survival advantage with the triplet regimen (12.3 versus
10.3 months),33 has established this combination as a new
first-line standard of care in selected patients with advanced
NSCLC. Results from studies in this setting must now be
considered in the context of the ECOG 4599 data. How-
ever, it is worth noting that the patient populations in the
current study and the ECOG 4599 trial differ somewhat
due to eligibility limitations for patients receiving bevaci-
zumab. The ECOG 4599 trial did not enroll patients with
a histology of squamous cell carcinoma, hemoptysis, his-
tory of hemorrhagic diathesis, or coagulopathy due to the
risk of serious hemorrhagic events, which limits the wide-
spread applicability of this triplet regimen.33
An additional reason for improved survival in S0339
may be the more widespread use of second-line therapy in
NSCLC, such as docetaxel, pemetrexed, and erlotinib, as
shown in Table 3. The median PFS of 5 months is similar to
that reported previously, 4 to 5 months,12,29–31 as is the ORR
of 23% and disease control rate of 68%.12,29–31
Therapy with bortezomib plus gemcitabine/carbopla-
tin was generally well tolerated. As expected the most
common grade 3/4 AEs were hematologic. Bortezomib-
induced thrombocytopenia and neutropenia have been de-
scribed as transient and cyclical, with rapid recovery of
platelet count and neutrophils toward baseline during the
rest period of each cycle, in studies in relapsed and/or
refractory multiple myeloma.34–36 While the hematologic
toxicity was not clinically significant in terms of AEs
(bleeding and febrile neutropenia), it resulted in a substan-
tial number of dose reductions (87%), which limited dose
intensity. Due to the conservative criteria for dose reduc-
tions for thrombocytopenia and neutropenia specified in
the protocol, they were commonly implemented and may
have affected efficacy by reducing the ability to deliver
full-dose gemcitabine/carboplatin.
Another common toxicity associated with bort-
ezomib in multiple myeloma studies is peripheral sensory
neuropathy.37,38 The overall incidence of grade 3/4 sensory
neuropathy seen in this study was lower than in studies of
bortezomib 1.3 mg/m2 in relapsed/refractory multiple my-
eloma37,38; this may be attributed to the lower dose of
bortezomib (1.0 mg/m2) used and the different patient
population.
Lastly, a biomarker for bortezomib sensitivity has yet
to be established. Considering the large number of potential
molecular targets of proteasome inhibition, it may be unlikely
that a single predictive biomarker will be identified. The
results of our study suggest that bortezomib-based combina-
tions could prove promising for advanced NSCLC, particu-
larly if a biomarker for efficacy could be identified to predict
which patients are most likely to benefit.
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